196 related articles for article (PubMed ID: 32861263)
1. Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab.
Zhong YY; McLean L; Buckle A; Siva S; Tran B
Can J Urol; 2020 Aug; 27(4):10339-10341. PubMed ID: 32861263
[TBL] [Abstract][Full Text] [Related]
2. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
[TBL] [Abstract][Full Text] [Related]
3. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
Tannir NM; Papadopoulos KP; Wong DJ; Aljumaily R; Hung A; Afable M; Kim JS; Ferry D; Drakaki A; Bendell J; Naing A
Int J Cancer; 2021 Jul; 149(2):403-408. PubMed ID: 33709428
[TBL] [Abstract][Full Text] [Related]
4. Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma.
Hashimoto M; Nakayama T; Fujimoto S; Inoguchi S; Nishimoto M; Kikuchi T; Adomi S; Banno E; De Velasco MA; Saito Y; Shimizu N; Mori Y; Minami T; Fujita K; Nozawa M; Nose K; Yoshimura K; Uemura H
Anticancer Drugs; 2022 Jan; 33(1):e818-e821. PubMed ID: 34486537
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib for the treatment of renal cell carcinoma.
Welsh SJ; Fife K
Future Oncol; 2015; 11(8):1169-79. PubMed ID: 25832874
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib-induced chylothorax in a patient with renal cell carcinoma.
Koylu B; Tekin F; Aktas BY; Kilickap S; Koksal D
Anticancer Drugs; 2022 Jan; 33(1):e555-e557. PubMed ID: 34387587
[TBL] [Abstract][Full Text] [Related]
8. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Erman M; Biswas B; Danchaivijitr P; Chen L; Wong YF; Hashem T; Lim CS; Karabulut B; Chung HJ; Chikatapu C; Ingles S; Slimane K; Kanesvaran R
BMC Cancer; 2021 Sep; 21(1):1021. PubMed ID: 34521387
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib-induced severe acute liver injury: A case report.
Choi JW; Yoo JJ; Kim SG; Kim YS; Chin S
Medicine (Baltimore); 2021 Nov; 100(46):e27731. PubMed ID: 34797298
[TBL] [Abstract][Full Text] [Related]
10. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.
Klempner SJ; Choueiri TK; Yee E; Doyle LA; Schuppan D; Atkins MB
J Clin Oncol; 2012 Sep; 30(27):e264-8. PubMed ID: 22802316
[No Abstract] [Full Text] [Related]
11. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
12. Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Shantakumar S; Nordstrom BL; Djousse L; Hall SA; Gagnon DR; Fraeman KH; van Herk-Sukel M; Chagin K; Nelson J
Cancer Chemother Pharmacol; 2016 Sep; 78(3):559-66. PubMed ID: 27438066
[TBL] [Abstract][Full Text] [Related]
13. Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.
Miaris N; Maltezou M; Papaxoinis G; Visvikis A; Samantas E
Clin Genitourin Cancer; 2017 Feb; 15(1):e99-e103. PubMed ID: 27601362
[No Abstract] [Full Text] [Related]
14. Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report.
van Kalleveen MW; Walraven M; Hendriks MP
Invest New Drugs; 2018 Jun; 36(3):513-516. PubMed ID: 29464464
[TBL] [Abstract][Full Text] [Related]
15. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes.
Henriksen JN; Bøttger P; Hermansen CK; Ladefoged SA; Nissen PH; Hamilton-Dutoit S; Fink TL; Donskov F
Clin Genitourin Cancer; 2020 Feb; 18(1):62-68.e2. PubMed ID: 31640912
[TBL] [Abstract][Full Text] [Related]
17. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
Asaithambi G; Peters BR; Hurliman E; Moran BP; Khan AS; Taylor RA
J Clin Pharm Ther; 2013 Apr; 38(2):175-6. PubMed ID: 23210935
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
19. Severe hyperglycaemia following pazopanib treatment: The role of drug-drug-gene interactions in a patient with metastatic renal cell carcinoma-A case report.
Kuruc Poje D; Božina N; Šimičević L; Žabić I
J Clin Pharm Ther; 2020 Aug; 45(4):628-631. PubMed ID: 32369219
[TBL] [Abstract][Full Text] [Related]
20. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
Grassi P; Verzoni E; Ratta R; Porcu L; Prisciandaro M; Mennitto A; Calareso G; de Braud F; Procopio G
Drugs R D; 2017 Sep; 17(3):461-467. PubMed ID: 28801802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]